Master of Ceremony: Day 1

Scott Budman Reporter & Anchor for business and technology news NBC Bay Area


Born and raised in Oakland, Scott has been with NBC Bay Area since 1995 as a reporter and anchor for business and technology news. Scott earned a degree in political science at UCLA. He began his broadcasting career in radio as a business reporter for KMNY radio in Anaheim. He then spent some time as a general assignment reporter and business anchor/producer at the Orange County News Channel. Before joining NBC Bay Area, Scott was a reporter and weekend anchor at KEYT in Santa Barbara. Scott has won many awards including a national Iris Award for a documentary about gays in the military. He also received Golden Mike Awards from the Southern California Radio and Television News Directors Association.In addition to his busy schedule at NBC Bay Area, Scott is a devoted volunteer with the Big Brothers Big Sisters of Santa Clara County. He also supports the Second Harvest Food Bank. During his down time, Scott enjoys sports such as tennis and basketball. He also loves reading and seeing his family. He lives with his wife and two daughters.

  Master of Ceremony: Day 2    
  Carolyn Johnson Anchor ABC7 News    
Most evenings, you’ll find Carolyn Johnson anchoring ABC7 News at 6 & 11 and reporting on health and science. In 2008 she celebrated 10 years with the station as an anchor and reporter; she won a regional Edward R. Murrow Award from the Radio and Television News Directors Association for best newscast; and she completed a health journalism fellowship with the California Endowment/USC Annenberg School of Communication. Carolyn brings more than 20 years of experience in television production and on-air work to her position. She began her career as an intern at KCBS-TV in Los Angeles, and then worked as a production assistant for ABC7 while still in college. She worked behind the scenes, producing numerous programs and specials at ABC7 before accepting a reporting position at KSBY-TV in San Luis Obispo. She returned to ABC7 in 1998 as a reporter and anchor. Carolyn’s industry recognitions include a 2009 Emmy Award for best evening newscast. She’s also been honored as best reporter by the American Women in Radio and Television, Golden Gate Chapter. Carolyn has won a Service to Children Award from the National Association of Broadcasters, the Eugene Block Journalism Award for Outstanding Coverage of San Francisco Human Rights Issues, the John Swett Award for Outstanding Locally Produced Education Series, the Arthritis Foundation Media Award and the Hero Award from the Neuropathy Action Foundation. She's also been recognized by RTNDA for her news reporting. Carolyn double majored in psychology and communication and graduated with honors from Stanford University.
  Leroy Hood, M.D., Ph.D. President of Institute for Systems Biology    

Dr. Hood’s research has focused on fundamental biology (immunity, evolution, genomics) and on bringing engineering to biology through the development of five instruments; the DNA and protein sequencers and synthesizers and the ink-jet oligonucleotide synthesizer (making DNA arrays) for deciphering the various types of biological information (DNA, RNA, proteins and systems). In particular, the DNA sequencer has revolutionized genomics by allowing the rapid automated sequencing of DNA, which played a crucial role in contributing to the successful mapping of the human genome during the 1990s and early 2000s. These instruments constitute the technological foundation for modern molecular biology and genomics. He has applied these technologies to diverse fields including immunology, neurobiology, cancer biology, molecular evolution and systems medicine. Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. Indeed, Dr. Hood is one of only 7 (of more than 6000 members) scientists elected to all three academies (NAS, NAE and IOM). Dr. Hood has also played a role in founding more than 14 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. He is currently pioneering systems medicine and the systems approach to disease and has recently cofounded the company Integrated Diagnostics—that hopefully will become a platform company for P4 medicine.

  Russ Altman, Ph.D. Professor of Bioengineering, Genetics & Medicine Stanford University    

Russ Biagio Altman is professor of bioengineering, genetics, & medicine (and of computer science by courtesy) and chairman of the Bioengineering Department at Stanford University. His primary research interests are in the application of computing technology to basic molecular biological problems of relevance to medicine. He is currently developing techniques for collaborative scientific computation over the Internet, including novel user interfaces to biological data, particularly for pharmacogenomics (e.g. Other work focuses on the analysis of functional microenvironments within macromolecules and the application of algorithms for determining the structure, dynamics and function of biological macromolecules (e.g. Dr. Altman holds an M.D. from Stanford Medical School, a Ph.D. in medical information sciences from Stanford, and an A.B. from Harvard College. He has been the recipient of the U.S. Presidential Early Career Award for Scientists and Engineers, a National Science Foundation CAREER Award. He is a fellow of the American College of Physicians and the American College of Medical Informatics. He is a past-president and founding board member of the International Society for Computational Biology, an organizer of the annual Pacific Symposium on Biocomputing. He leads one of seven NIH-supported National Centers for Biomedical Computation, focusing on physics-based simulation of biological structures (   He won the Stanford Medical School graduate teaching award in 2000.

  Dr. Michael D. Amos Biosciences Advisor to the Director of the Chemical Science and Technology Laboratory, National Institute of Standards and Technology (NIST), Technology Administration, U.S. Department of Commerce  
Dr. Michael D. Amos has held various industry research, marketing and business development positions in the fields of biopharmaceuticals, neutraceuticals, drug delivery, transgenics, immunodiagnostics, molecular biology and molecular pathology. He is also a founder of two biotechnology companies. Dr. Amos joined NIST in 2002 as a Program Manager and Biologist in the Chemistry and Life Sciences Office of the Advanced Technology Program (ATP), an extramural funding arm of NIST. At ATP, he participated and led evaluation of biotechnology proposals for funding and managed projects on stem cells, nanotechnology, immunotherapeutics, cancer vaccines, neurobiology, protein therapeutics, drug discovery, gene therapy, metabolic engineering, and medical devices. Mike joined CSTL in 2006, and serves as biosciences advisor to Dr. Willie May as a liaison to industry, academia and other government agencies in the bioscience and health care areas. Dr. Amos serves as the Department of Commerce representative on the Department of Health and Human Services Secretary’s Advisory Committee on Genetic, Health and Society (SACGHS). Dr. Amos is a leader in the field of autoimmune immunodiagnostics and serves on the Autoimmune Disease Coordinating Committee of the National Institutes of Health.
  Amos Barzilay Venture Consultant Walden International  

Until recently, Dr. Barzilay was the interim CEO of CollaBrx, a biotechnology company whose goal is to help oncologists develop customized therapies for cancer patients who are unresponsive to standard treatments.  Dr. Barzilay is a Venture Consultant and was a General Partner with Walden International, a global Venture Capital firm with over $2 billion under management. At Walden Dr. Barzilay led several investments in innovative software companies and served on their boards. Prior to joining Walden Dr. Barzilay was Vice President & General Manager, Content and Supplier Solutions in Commerce One. Dr. Barzilay joined Commerce One as part of Commerce One's acquisition of Mergent Systems in January 2000. Dr. Barzilay was a co-founder, chairman, and CEO of Mergent Systems, a business-to-business e-commerce infrastructure start-up. Prior to Mergent, Dr. Barzilay held a variety of senior management positions including General Manager of C*ATS,  senior marketing executive at Informix and CEO at Syntelligence Systems. Prior to Syntelligence, Dr. Barzilay was an AI researcher at Xerox Parc. Dr. Barzilay has an engineering degree from the Technion in Israel and an M.B.A. and Ph.D. degree from the University of Pittsburgh.

  Paul Billings, M.D., Ph.D. Director and CSO, Genomic Medicine Institute El Camino Hospital  
Dr. Paul Billings, a board certified internist and clinical geneticist, is the founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital in Mountain View, CA. This new center seeks to serve the health needs of the greater Silicon Valley by providing its leading community hospital and providers with advanced and top quality access to new genomic technologies. Dr. Billings served as President, Chief Executive Officer and Director of CELLective Dx Corporation (CLDx; fka Cellpoint Diagnostics [CPD]) from November, 2007 through January, 2009. CLDx, a Mohr, Davidow Ventures backed enterprise, sought to revolutionize cancer care through the provision of microfluidic products and services focused on circulating tumor cells. The company merged with Exalan, Inc., based in Cambridge, MA in April, 2009. Dr. Billings is a Founder of CBR Systems Inc., the worldwide leader in cordblood stem cell banking, and GeneSage Inc., an early provider of expert genomic information and testing on-line. He has also been Executive Chairman of Signature Genomics Laboratories LLC (SGL), the leading national provider of molecular cytogenetic products and services. He has served on the Board of Directors of CLDx, SGL, BioScale Inc., Cyntellect Inc., and Lipomics, Inc. (recently purchased by Tethys Biosciences Inc. where he is a Board Observer) and several not-for-profit public interest organizations including the Council for Responsible Genetics, the oldest public interest group actively reviewing developments in biotechnology. He is a member of the HHS Secretary’s Advisory Committee on Genomics, Health and Society, the NIH Special Study Section on Salivary Diagnostics, and the Genomics Oversight Committee of the Department of Veterans Affairs (awaiting final approval). For five years until September 2007, he was Senior Vice President and Senior Geneticist at Laboratory Corporation of America Holdings Inc (LH). Prior to joining LH, Dr. Billings was Deputy Chief of Staff and Chief of General Internal Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. He has been Professor of Anthropology (adjunct) at the University of California at Berkeley and has published extensively on topics in immunology, genetics and medicine. Dr. Billings graduated with an AB in History summa cum laude from UC San Diego, received both his MD and PhD degrees from Harvard University where he worked with Nobel Laureate, Dr. Baruj Benacerraf, and has interest in diagnostics for medical care and genomic medicine.
  Trisha Brown, M.S., CGC VP Clinical Affairs DNA Direct  

Trish Brown is an executive with over 15 years of experience in the business of medical genetics. She is a board-certified genetic counselor with a passion for personalized medicine and consumer advocacy. Prior to joining DNA Direct, Trish was an Associate Vice President at LabCorp and Director of Strategic Technology Management and Implementation. In this role she oversaw the commercialization of new technologies and developed expertise in operations, project management, strategic planning, and product development. She was also responsible for LabCorp’s genetic information services which included a specialized genetics call center and clinical genetic counseling services. Trish received her undergraduate degree in Genetics at the University of California, Davis. She obtained her genetic counseling degree at Sarah Lawrence College, and then practiced prenatal and craniofacial genetic counseling at St. Peter’s Medical Center in New Brunswick, New Jersey. Her next career step was at Duke University Medical Center in the Maternal Fetal Medicine department where she provided prenatal counseling and was on the Faculty for the Department of Pediatrics and Genetics for the Medical Genetics Fellowship Program. Trish has authored over forty five peer reviewed posters, publications, and presentations. She is a member of the National Society of Genetic Counselors, Women Business Leaders of the U.S.

  Brook Byers Parter KPCB  

Brook Byers has been a venture capital investor since 1972. He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies. He formed the first Life Sciences practice group in the venture capital profession in 1984 and led KPCB to become a premier venture capital firm in the medical, healthcare, and biotechnology sectors. KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients. Brook was the founding President and then Chairman, of four biotechnology companies which were incubated in KPCB's offices and went on to become public companies with an aggregate market value over $8 Billion. He is currently on the Board of Directors of ten companies, most recently joining CardioDX, Genomic Health Incorporated, Five Prime Therapeutics, OptiMedica, Pacific Biosciences, Inc., Tethys and XDx, Inc. He was formerly a Director of Idec Pharmaceuticals (Chairman), Athena Neurosciences (Chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Onyx Pharmaceuticals, Hybritech (Chairman), Genprobe and others. These companies have pioneered the medical use of molecular biology, monoclonal antibodies, personalized medicine, molecular diagnostics and genomics. Brook was President and a Director of the Western Association of Venture Capitalists. He is a currently a Board member of the University of California at San Francisco Medical Foundation, the New Schools Foundation, Stanford’s Bio-X Advisory Council and the Stanford Eye Council. He was Co-Chair of the five year, $1.4 billion, UCSF Capital Campaign. In 2007, he was awarded the “UCSF Medal” as their honorary degree equivalent. In 2008, he was elected a Fellow of the American Academy of Arts and Sciences. In 2009, he received the Lifetime Achievement Award from the National Venture Capital Association. He was formerly a Director of the Entrepreneurs Foundation, the California Healthcare Institute, the Asian Art Museum in San Francisco, the Stanford Graduate School of Business Advisory Council, That Many May See (UCSF) Vision Research Foundation (Chairman), the Georgia Tech Advisory Board and was a founder of TechNet.

  Michael Cantor, M.D. Director of Healthcare Informatics Pfizer    
Michael Cantor joined Pfizer’s Healthcare Informatics group in February 2008. His work focuses on the secondary use of clinical data, personalized medicine, and automated methods for pharmacovigilance. At Pfizer, he is leading the PEER (Pfizer Externally Enabled Research) initiative, which aims to partner with academic medical centers to perform observational studies using data from electronic medical record (EMR) systems. He also helped lead Pfizer’s efforts with the e-Health Initiative’s Connecting Communities for Drug Safety, a partnership between academia and the pharmaceutical industry exploring the use of EMRs for pharmacovigilance. He is a member of Pfizer’s Personalized Medicine SMART team, and helped organize Pfizer’s Personalized Medicine symposium, held in September 2008. Prior to joining Pfizer, Michael was the Chief Medical Information Officer for the South Manhattan Healthcare Network of the New York City Health and Hospitals Corporation, based at Bellevue Hospital in Manhattan. His work there focused on developing the network’s EMR system to improve patient safety and on using the network’s clinical data warehouse for research. He continues to see patients 1 day/week at Bellevue , and is a Clinical Assistant Professor of Medicine at NYU School of Medicine. Michael completed his residency in internal medicine and informatics training at Columbia, has an M.D. from Emory University, and an A.B. from Princeton.
  Rowan Chapman, Ph.D. Partner at MDV    
Rowan Chapman joined MDV in 2001 to focus on life science investments. Her interests lie in the translation of complex data and technology to innovative products that impact drug and biofuel discovery, personalized medicine and healthcare decision making. Leveraging her business and technical experience as well as industry relationships she partners closely with entrepreneurs to help develop successful businesses. She partners with entrepreneurs in a "hands on" role to help get companies started and financed. Rowan is a board member of iAccessCare and MLC Dx and a board observer at Artemis Health, Pacific Biosciences, Adamas Pharmaceuticals, ParAllele BioScience (acquired by Affymetrix) and Tethys Biosciences. Rowan is also a member of the Personalized Medicine Coalition. Prior to joining MDV Rowan held the position of director of business development at Rosetta Inpharmatics (acquired by Merck) where she established collaborative partnerships with organizations in the pharmaceutical, agricultural and biotech fields as well as among various research institutions. Previously, Rowan held the position of marketing manager at Incyte Genomics. Rowan holds a Ph.D. in cellular and molecular biology from the MRC Laboratory of Molecular Biology in Cambridge University, UK where she also earned a bachelor's degree with first class honors in Biochemistry. She served postdoctoral fellowships at the University of California, San Francisco, as well as at the MRC-Laboratory of Molecular Biology at Cambridge. Prior to her work in industry, she authored or co-authored more than a dozen articles and patents.
  Esther Dyson Founder EDventure Holdings  

Esther Dyson does business as EDventure Holdings, the reclaimed name of the company she owned for 20-odd years before selling it to CNET Networks in 2004. In the last few years, she has turned her sights towards IT and health care. She dedicated two issues of her newsletter, Release 1.0, to the topic (Health and Identity: No Patient Left Behind? in January 2005 and Personal Health Information: Data Comes Alive! in September 2005). Also in September 2005, she ran the Personal Health Information workshop that laid out many of the challenges still perplexing the health-care community. Currently, she is one of the initial ten subjects of George Church's Personal Genome Project. Her primary activity is investing in start-ups and guiding many of them as a board member. Her board seats include Boxbe, CVO Group (Hungary),, Evernote, IBS Group (Russia, advisory board), Meetup, Midentity (UK), NewspaperDirect, and WPP Group and Yandex (Russia). Some of her past direct IT investments include Flickr,, BrightMail, Medstory and Orbitz. Dyson was the founding chairman of ICANN from 1998 to 2000, and was also chairman of the Electronic Frontier Foundation in the 90's. In 1997, she wrote Release 2.0: A Design for Living in the Digital Age, which appeared in paperback a year later as Release 2.1. In 1994, she wrote a seminal essay on intellectual property for Wired magazine.

  Jennifer Fonstad Managing Director Draper Fisher Jurvetson  
Jennifer Scott Fonstad is a Managing Director of Draper Fisher Jurvetson. Considered one of the most senior women in venture today, Ms. Fonstad invests broadly in early stage companies, most recently taking an early leadership role in clean energy. Additionally, she has been working to change our country’s healthcare system through entrepreneurship. Recent investment successes include Athenahealth (NASDAQ: ATHN), Lumenos (acquired by Wellpoint, NYSE: WLP), and NetZero (NASDAQ: UNTD). In addition to her investing responsibilities, Jennifer sits on the investment committees for DFJ VinaCapital, DFJ’s partner fund in Vietnam, DFJ Tamir Fishman, DFJ’s partner fund in Israel, and serves as adviser to the DFJ China team. Jennifer joined DFJ as a Kauffman Fellow in 1997 becoming a partner in 1998. She began her career with Bain and Company after spending a year teaching math to high school students in sub-Sahara Africa. She graduated Cum Laude from Georgetown University and holds an MBA with Distinction from the Harvard Business School. Jennifer is married with four children.
  Michael A. Goldman, Ph.D. Department of Biology Prof. & Chair San Francisco State University  
Dr. Goldman did his undergraduate work in Biology at the University of Rochester and obtained a Ph.D. in evolutionary biology at Purdue University in 1981. He completed fellowships in Medical Genetics at Baylor College of Medicine in Houston and at the University of Washington in Seattle. He joined the faculty at San Francisco State University in 1988, where he is now Professor and Chair of the Department of Biology. He teaches human genetics at the graduate level, general genetics for biology majors, developmental biology for Cell & Molecular Biology majors, and an interdisciplinary course on the ethical issues in science and technology. Dr. Goldman's research is in chromatin structure and the regulation of gene expression during mammalian development. Of special interest is the relationship between chromosome structural elements called nuclear matrix attachment regions (MARs) as boundaries of functional chromatin domains, studied through molecular methods and bioinformatics. He sees the public understanding of science as a key need if science and society are to thrive, and has talked about various issues like stem cell biology for TV and radio call-in audiences. He has written Op-Ed pieces for the Los Angeles Times, the Sacramento Bee, and the San Francisco Chronicle as well a professional papers appearing in Science and Nature Genetics. Thinking that the public learns much about science and bioethics from fiction, he reviews novels addressing various aspects of genetic science and its implications, in venues like Nature, Science, Nature Genetics and the San Francisco Chronicle.
  Hank Greely, Ph.D. Deane F. and Kate Edelman Johnson Professor of Law Stanford University  

A leading expert on the legal, ethical, and social issues surrounding health law and the biosciences, Hank Greely (BA ’74) specializes in the implications of new biomedical technologies, especially those related to neuroscience, genetics, and stem cell research. He frequently serves as an advisor on California, national, and international policy issues. He is chair of California’s Human Stem Cell Research Advisory Committee and a co-director of the Law and Neuroscience Project, funded by the MacArthur Foundation. Active in university leadership, Professor Greely chairs the steering committee for the Stanford Center for Biomedical Ethics and directs both the law school’s Center for Law and the Biosciences and the Stanford Center for Biomedical Ethics’ Program in Neuroethics. Professor Greely serves on the Scientific Leadership Council for the university’s interdisciplinary Bio-X Program. Before joining the Stanford Law School faculty in 1985, Greely was a partner at Tuttle & Taylor, served as a staff assistant to the secretary of the U.S. Department of Energy, and as special assistant to the general counsel of the U.S. Department of Defense. He served as a law clerk to Justice Potter Stewart of the U.S. Supreme Court and to Judge John Minor Wisdom of the Court of Appeals for the Fifth Circuit.Greely is also a professor (by courtesy) of genetics at Stanford School of Medicine.

  Mary Haak-Frendscho, Ph.D. President and CSO Takeda Pharmaceuticals San Francisco  
Mary Haak-Frendscho is President and Chief Scientific Officer of Takeda San Francisco, responsible for establishing Takeda's new center of excellence for biologics, which also serves as the therapeutic antibody IND engine for Takeda Pharmaceuticals. Dr. Haak-Frendscho leads the overall discovery and preclinical development, as well as actively expanding Takeda's US science, business, and intellectual property presence.   She has nearly 20 years of biopharmaceutical and biotechnology experience, is an inventor on over 25 issued and pending patents, authored about 70 scientific articles, and has an adjunct appointment at the University of Wisconsin
  Gregory Heath, Ph.D. Sr. VP & General Manager, Diagnostics Business Unit Illumina  
Greg Heath is responsible for managing Illumina’s emerging diagnostics business, specifically overseeing the development of diagnostic content for the BeadXpress system, and ultimately for the Illumina’s sequencing platform. Greg has more than 20 years of experience in the diagnostics field, including launching the first FDA-approved microarray for diagnostic use. Greg joined Illumina from Roche Molecular Systems where he held a number of senior executive positions including head of clinical genomics, senior vice president of global product marketing, senior vice president of global marketing and business development, and most recently, senior vice president of global business. In this last role, Greg was responsible for new product development and global marketing activities for the infectious disease, blood screening, genetics and oncology portfolios. Greg was also responsible for the PCR licensing, industrial business, and business development programs. From 2000–2003, Greg was head of business development and licensing for the diagnostics division of F. Hoffman La Roche in Basel and led the strategic planning, business development, and licensing activities of the molecular diagnostics, centralized diagnostics, applied science, near patient testing, and diabetes care business areas. Prior to this, Greg held numerous roles in marketing and business development with Roche Diagnostics’ U.S. affiliate.
Richard Deane Hockett, M.D. Chief Medical Officer, Affymetrix    
Richard D. Hockett’s current position is Chief Medical Officer, Affymetrix, Santa Clara, CA.  His responsibilities include translation of genomics technologies, medical and regulatory affairs.  Special areas of focus are molecular diagnostics, clinical application of technology, and biomarker strategies.  Prior to joining Affymetrix, Dr. Hockett was a Medical Fellow II, Group Leader for Genomic Medicine at Eli Lilly and Company, where he developed the pharmacogenomic program and oversaw the application of genetic biomarkers to clinical drug development.  While there he was instrumental in developing the DMET analysis system.    Prior to joining Lilly, Dr. Hockett was employed by the University of Alabama at Birmingham in the Department of Pathology, where he oversaw the Clinical Immunology and Molecular Diagnostic Laboratories.  His research interests have been in the areas of Developmental Immunology and HIV disease.  Dr. Hockett received his M.D. degree from the University of Minnesota, and did his residency in Clinical Pathology at Washington University, St. Louis.
Scott Jenkins, Ph.D. Director of Healthcare/Life Sciences Solution Sales Dell Healthcare  
Dr. Jenkins is currently the Director of Healthcare/Life Sciences Solution Sales with Dell Healthcare. In this role he is responsible for working closely with business partners to bring solutions to the marketplace that transformer the delivery of health Science. His team works to enable new solution with partners and new route for delivery of those products to the marketplace. Dr. Jenkins left his position as the VP of Business Development for TransMed partners, an international consulting firm focused on developing Information Based Medical solutions for Healthcare organizations to join Dell Healthcare. Previously Dr. Jenkins was the Vice President of Worldwide Marketing for Applied Biosystems, one of the largest multinational scientific instrumentation companies in the world. The AB technology was the principle methodology that allows for the continued understanding of the human genome project, most DNA forensic identification, and the expanding healthcare area of the genetic testing. Before joining AB, Dr. Jenkins was the WW Segment Executive for Pervasive Healthcare for IBM Healthcare & Life Sciences division. He joined IBM Life Sciences in 2001 and has managed the relationships with strategic device and diagnostic business partners. Prior to joining IBM Life Sciences, Dr. Jenkins had been the COO of Comgenex international, a combinatorial chemistry and software company. Before to joining Comgenex international, Dr Jenkins was the worldwide manager of Life Sciences for Apple Computer where he focused on bringing new solutions to the Mac platform. Earlier in his career, Dr. Jenkins spent 8 years as a research scientist and business development executive at both NutraSweet and Sandoz. During his career in the Life Sciences Industry, Dr. Jenkins played a significant role in the development of several new businesses including, Willstein Scientific Software, NSC Technologies, and Tap Data. As a serial entrepreneur, Dr Jenkins continues to work with Venture firms and start-ups to spark new businesses.
  Deval A. Lashkari Partner Telegraph Hill Partners

Dr. Lashkari has worked in the life sciences area since 1988 developing and commercializing novel technologies. He gained corporate and business development experience through senior management positions in a number of biotechnology companies. In addition, he was a founding Research Director at Synteni, which was acquired by Incyte Genomics, where he was Director of Product Development. He also worked with Operon Technologies, acquired by Qiagen, and Genometrix. Dr. Lashkari has represented THP on the boards of AcroMetrix, Althea Technologies, Applied Precision, Aurora Discovery and SwitchGear Genomics. Dr. Lashkari received a BA from the University of California, Berkeley and a Ph.D. from Stanford University.

Vijay Lathi Managing Director New Leaf Venture Partners  

Vijay Lathi is a Managing Director and concentrates primarily on our diagnostics and pharmaceuticals investments. Vijay joined Sprout in 1998 after working as an analyst in the Healthcare Venture Capital Group at Robertson Stephens & Co. and Cornerstone Research, a consulting firm focused on financial and economic analysis for business litigation. Vijay graduated from the Massachusetts Institute of Technology and Stanford University where he received his B.S. and M.S. in Chemical Engineering, with an emphasis on the application of engineering to life science technology. Vijay is also a member of AiCHE.

Elizabeth Mansfield, Ph.D. Director of the Personalized Medicine Staff FDA Center for Devices  
Dr. Mansfield is the Director of the Personalized Medicine Staff in the Office of In Vitro Diagnostic Devices in the Center for Devices, FDA, where she is developing a program to address companion and novel diagnostic devices.  She was previously a Senior Policy Analyst in the Office of In Vitro Diagnostic Devices (OIVD), managing policy and scientific issues. Dr. Mansfield formerly served as the Director of Regulatory Affairs at Affymetrix, Inc, 2004-2006.  She previously served in other positions at FDA including Scientific Reviewer, Genetics Expert. Dr. Mansfield received her PhD from Johns Hopkins University, and completed further postdoctoral training at the National Cancer Institute (NCI) and the National Institute for Arthritis, Musculoskeletal, and Skin Diseases (NIAMS).

Ariel Miller, M.D., Ph.D. Pharmacogenetics & Personalized Medicine Center, Rappaport Faculty of Medicine & Research Institute Technion-Israel Institute of Technology, Israel


Prof. Ariel Miller holds a M.D. degree from the “Sackler” school of Medicine, Tel-Aviv, and a Ph.D. degree in Experimental Sciences (Neurobiology) from the Hebrew University of Jerusalem. He is a senior neurologist since 1989. From 1989 to 1992 he was a research fellow at the Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, as a scholar of the Fogarty International Research Fellowship (N.I.H.). From 1992 to 1993: Scientist in the Department of Cell Biology, The Weizmann Institute of Science, Rehovot, Israel. He is currently the head of The Center for Multiple Sclerosis & Brain Research at Carmel Medical Center, associated with The Rappaport Institute for Research in the Medical Sciences, and the Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.Prof. Miller is elected member of the American Neurological Association (ANA) (2005), and the recipient of the Hershel Rich Technion Innovation Award – 2006, for his contribution in the field of Pharmacogenetics and 'Personalized Medicine'.Prof. Miller's scientific and medical work is dedicated to elucidation of the mechanisms underlying Brain diseases, with special focus on implementation of therapeutic strategies for Multiple Sclerosis as well as Pharmacogenetics towards development of 'Personalized Medicine'.

  Robert Nussbaum, M.D. Holly Smith Distinguished Professor in Medicine & Chief, Medical Genetics UCSF    

Dr. Nussbaum has his research efforts in three main areas. The first is an investigation of the genetic contribution to Parkinson disease (PD). Beginning ten years ago, in collaboration with his colleague Dr. Mihael Polymeropoulos, his group identified the first mendelian-inherited form of PD, a mutation in the gene encoding alpha-synuclein. Since then, he has been working to identify other inherited forms of the disease through family studies. Although inherited forms of PD are rare, the opportunity to discover and understand the pathogenetic mechanisms in rare hereditary forms of the disease gives insight into the pathways and processes that may be involved in the more common, sporadic forms. Dr. Nussbaum is using the information gained from the hereditary forms of the disease to develop disease models in mice using transgenic technology. A second area of research in the Nussbaum lab is a longstanding effort to understand the rare X-linked disease known as the oculocerebrorenal syndrome of Lowe (OCRL), characterized by congenital cataracts, Fanconi syndrome of the renal proximal tubules, neurological dysfunction, and developmental delay. Current treatment is purely symptomatic and palliative. Dr. Nussbaum discovered the gene responsible for OCRL by positional cloning and demonstrated that the gene encodes a phosphatidylinositol (4,5) bisphosphate 5-phosphatase that was shown to be enriched in the trans-Golgi network and early endosomal compartments. The relationship between the enzyme deficiency and the pathophysiological abnormalities in OCRL remain obscure. Surprisingly, mice engineered to lack the OCRL gene have no signs of the disease. Dr. Nussbaum is investigating why mice are protected from a deficiency in this enzyme and how this information might be exploited to expand our understanding of this enigmatic disorder and develop new, specific therapies.

  Kathryn A. Phillips, Ph.D. Professor of Health Economics & Health Services UCSF    
Kathryn A. Phillips PhD is Professor of Health Economics and Health Services Research with a primary appointment in the Department of Clinical Pharmacy at the UCSF School of Pharmacy and secondary appointments in the UCSF Philip R. Lee Institute for Health Policy Studies, and the UCSF Comprehensive Cancer Center. Dr. Phillips received her PhD in Health Services Research and Policy Analysis with a specialty in Health Economics from the University of California-Berkeley, her Masters degree in Public Administration with an emphasis on Policy Analysis from Harvard University, and her BA in Psychology (with high honors) from the University of Texas at Austin. Dr. Phillips’ research focuses on how health care is organized, delivered, and financed in the US. She focuses on personalized medicine – specifically, targeting health care interventions to patients based on their genetics – and the impact of personalized medicine on clinical care, health economics, and health policy, particularly in the area of cancer screening and treatment. She is serving as the Prinicipal Investigator on several NIH and foundation grants, has led or participated in approximately 35 funded research grants, and has had continuous funding from the NIH throughout her career. Dr Phillips has developed a 4-year, $6 million research program on Personalized Medicine for Colorectal and Breast Cancer and has been funded by the Blue Shield of California Foundation to examine the policy challenges for personalized medicine. Dr. Phillips serves as an adviser to many government and industry groups including the Institutes of Medicine; Food and Drug Administration; Secretary of Health and Human Services Office; Secretary’s Advisory Committee on Genetics, Health, and Society; the Centers for Disease Control and Prevention; the National Cancer Institutes; and the President’s Council of Advisors on Science and Technology as well as start-up companies and venture capital firms. Dr. Phillips has published ~ 100 peer-reviewed articles in policy and clinical journals, including JAMA, New England Journal of Medicine, and Health Affairs and serves on the editorial board for four journals.

Stephen Quake, Ph.D. Professor of Bioengineering Stanford University


Dr. Stephen R. Quake's research interests lie at the nexus of physics, biology and biotechnology, focusing on understanding the basic physics and biological applications of microfluidic technology. His achievements include developing new forms of biological automation and applying these tools to problems of biological and medical interest, including structural genomics, systems biology, microbial ecology and nanoliter-scale synthetic chemistry. Dr. Quake pioneered the development of Microfluidic Large Scale Integration (LSI), demonstrating the first integrated microfluidic devices with thousands of mechanical valves. This technology is helping to pave the way for large scale automation of biology at the nanoliter scale. Commercial versions of microfludic LSI are now used in hundreds of laboratories around the world for diverse purposes. Dr. Quake demonstrated the first successful single molecule DNA sequencing technology. His contributions to genomics include the first measurement of the immune repertoire of an organism. In 2009 he and two co-workers sequenced his personal genome using the commercial version of the single molecule sequencing technology that he developed. Dr. Quake is Professor of Bioengineering at Stanford University and a Howard Hughes Medical Institute Investigator. He received a BS in physics and MS in mathematics from Stanford University, and his PhD in physics from Oxford University as a Marshall Scholar. Dr. Quake has received numerous career awards, including “Career” and “First” awards from the National Science Foundation and National Institutes of Health. He is a founder and scientific advisory board chair of Fluidigm, Inc. and Helicos Biosciences, Inc.


Bruce Quinn Senior Health Policy Specialist Foley Hoag


Bruce Quinn, M.D., Ph.D., MBA, formerly the Contractor Medical Director for the California Medicare Part B program, practices within the firm’s Government Strategies practice, where he focuses on Medicare coverage and payment matters for new technologies. Bruce is a national leader in the areas of Medicare coverage and payment, claims and billing, and Medicare contractor reform processes. Dr. Quinn works with companies, providers and venture capital investors to develop strategies for Medicare payment for new technologies. A large part of this work is on local and national coverage decisions. Bruce focuses, in particular, in the emerging field of molecular diagnostics and personalized medicine. He also advises clients on Medicare Administrative Contractor (MAC) reform and its effect on payment policy. Before serving in the Medicare Part B program, Bruce was a physician executive in the Health & Life Sciences division of Accenture and was a clinician-scientist at Northwestern University School of Medicine, leading pathology research for Northwestern’s NIH-funded Alzheimer Research Center. He also held academic positions at New York University School of Medicine and UCLA Center for Health Sciences.

  Barbara Ralston Vice President Guest Services and International Medicine Stanford Hospital and Clinics.  

Barbara Ralston is the Vice President for Guest Services and International Medicine at Stanford Hospital and Clinics.  She is responsible for strategic planning and implementation of programs for in- and out- patient and visitor services that translate to a reputation of world-class service for Stanford Hospital and Clinics. Stanford’s Executive Health, Corporate Partners, and Aging Adult Programs are key components of her operation.

Barbara has been at Stanford Hospital since 1989. Her background is in health and administration. Previously a consultant with Arthur D. Little, Inc., she holds a B.S. in Medical Microbiology from Stanford University, an MT(ASCP) clinical laboratory certification, and an M.Sc. in Demography and Public Health from London School of Hygiene and Tropical Medicine, University of London.

  Clifford Reid, Ph.D. Chairman, President & CEO Complete Genomics    
Dr. Clifford Reid, chairman, president and chief executive officer of Complete Genomics, has 25 years of experience in startup and growth companies managing the commercialization of innovative, unstructured data management technologies. In 1995, he was the founding chairman and chief executive officer of Eloquent, Inc., a digital video communications company that he took public in 2000 (NASDAQ: ELOQ) and sold it in 2003. In 1988, he was the founding vice president of product development at Verity (NASDAQ: VRTY), an enterprise text search engine company that was recently sold to Autonomy for $500M. Cliff earned a B.S. in physics from the Massachusetts Institute of Technology (MIT), an M.B.A. from the Harvard Business School and a Ph.D. in management science and engineering (MSE) from Stanford University.

Hakan Sakul, Ph.D. Sr. Director and Global Head of Diagnostics and Oncology Pfizer


Hakan serves as the Global Head of Diagnostics and Oncology Leads, leading Pfizer’s Diagnostics efforts across its pharmaceutical portfolio.  He received his BS and MS degrees from Ankara University in Turkey.  He completed his PhD degree in Quantitative Genetics from the University of Minnesota as the recipient of a “Freedom from Hunger” Scholarship from The Rotary Foundation in its inaugural year in 1986.  Following a postdoctoral program at the University of California-Davis, Hakan worked in the biotech industry in human genetics, pharmacogenomics and statistical genetics.  His entry into the pharmaceutical industry was through Parke-Davis Pharmaceuticals – Warner Lambert as Director of Human Genetics, Statistical Genetics and Pharmacogenetics programs.  Following the merger of W-L and Pfizer, Hakan served as Site Head for Clinical Pharmacogenomics in Pfizer’s Connecticut site.  Hakan assumed his current role in mid-2007.  A member of the Editorial Board of the Personalized Medicine Journal, the Organizing Committee of the annual Personalized Medicine meeting at Harvard, and the author of over 30 scientific refereed articles and several book chapters, Hakan has served as an invited speaker on many panel discussions and scientific meetings.  His external representation of Pfizer includes memberships on the Clinical Science and Technology Committee of The Personalized Medicine Coalition, the Research Tools and Molecular Diagnostics Sub Team of BIO, and the California Healthcare Institute Diagnostics Working Group.  Hakan is keenly interested in applications of companion diagnostics, pharmacogenomics and related technologies to the pharmaceutical pipeline to advance Personalized Medicine for the improvement of individualized healthcare.

  Cecilia Schott, Ph.D., MBA Business Development Director, Personalized Healthcare AstraZeneca    

Cecilia Schott is the Business Development Director in AstraZeneca’s Personalized Healthcare group. She is responsible for identifying, evaluating and facilitating interactions with diagnostics partners for implementation of personalized healthcare strategies in drug development. Cecilia has 20 years of professional experience in healthcare including biotech, device and pharmaceutical industries with a focus in drug development and commercialization. Prior to joining AstraZeneca Cecilia held positions at Biogen, Boston Scientific and St. Elizabeth Medical Center in Boston.

  Sue Siegel Partner MDV    
Sue Siegel brings 25 years experience commercializing key enabling technologies in biomedical research and healthcare. She leads investments in personalized medicine spanning areas that include technology platforms to molecular diagnostics to online healthcare, all of which leverage the power of cross-disciplinary convergence. She partners with entrepreneurs that offer "disruptive innovation" business solutions to pressing healthcare challenges: age-onset and lifestyle-induced health conditions, consumer-driven wellness preservation, and those that improve healthcare economics. Prior to joining MDV, Sue was President and Director of Affymetrix, Inc., a company that pioneered GeneChip®technology and was instrumental in the expansion of genomics-based personalized medicine. During her tenure, she grew Affymetrix to become a multibillion dollar market cap company. At Amersham International (now GE), she held several senior executive roles, including President of Hoefer-Pharmacia Biotech. At Amersham, Sue played a key role in growing businesses through acquisitions and via the commercialization of novel enabling technologies. She was also involved in commercializing key biomedical technologies at E. I. DuPont & Co., Eastman Kodak Co., and Bio-Rad Laboratories. Sue serves on the board of The Tech Museum of Innovation, is a member of the Presidents' Circle of the National Academies, and serves as an advisor to the Institute of Medicine. As Chair of the Community Relations Committee of The Gladstone Institute in San Francisco, she leads the effort to expand this leading biomedical research organization to the global community. Sue was elected as a Henry Crown Fellow of the Aspen Institute in 2003. As part of this Fellowship, she co-founded at the Stanford Hospital Geriatric Department, Checking-In™, an organization dedicated to serving our aging population. She is a Council member for the Institute for Immunity, Transplantation, and Infectious Diseases (ITI) at Stanford Medical School and is an Officer of the Golden Gate Chapter of YPO. Sue has served as a Regional Panelist for the selection of White House Fellows, on the Council on Biotechnology Research, Innovation, and Public Policy for the Center for Strategic and International Studies (CSIS), and on the IBM Life Sciences and Healthcare Strategic Advisory Council. Sue received a M.S. in Biochemistry and Molecular Biology from Boston University Medical School where she studied cellular differentiation in mouse embryonic carcinoma stem cells. She received her B.S. in Biology from the University of Puerto Rico.
  John Steuart Managing Director Claremont Creek Ventures    
John has spent the last 20 years managing, building and investing in technology and life science companies. John focuses on the intersection of the information technology and life sciences markets including bioinformatics, molecular diagnostics, genomics, proteomics, software and instrumentation for med-tech industries. John serves on the board of directors of Arcxis, Tibion, Fluxion, Gene Security Network and Wired Benefits. He is an Industry Fellow at the Center for Entrepreneurship and Technology at the College of Engineering as well as a member of the Advisory Council to the Lester Center's Berkeley Entrepreneurs' Forum at UC Berkeley. Early in his career, he joined Alafi Capital, an Emeryville-based venture firm specializing in early-stage biomedical companies, where he served as an officer of the General Partner. At Alafi, John lead investments in more than a dozen successful start-ups, and served as the senior executive and board member of various firms such as Tanox, Software Ventures, Lipomatrix and Megan Health. In the mid-90s, together with colleague Nat Goldhaber, John helped start Cybergold, an Internet marketing and payments company, serving as the early COO and CFO through its IPO, merger with Mypoints and sale to United Airlines. John continued with the Mypoints unit of United serving as the Senior Vice President of Strategic Partnerships.
  Tanveer Syeda-Mahmood Ph.D. Research Manager Multi-modal Mining for Healthcare IBM  

Dr. Syeda-Mahmood is a research manager in the Health care Informatics department at the IBM Almaden Research Center. She currently leads the AALIM project on multimodal mining for healthcare. Dr. Syeda-Mahmood graduated from the MIT AI Lab in 1993 with a Ph.D in Computer Science. Prior to IBM, she worked as a Research Staff Member at Xerox Webster Research Center, Webster, NY. She joined IBM Almaden Research Center in 1998. Prior to coming to IBM, Dr. Syeda-Mahmood led the image indexing program at Xerox Research and was one of the early originators of the field of content-based image and video retrieval. Currently, she is working on applications of content-based retrieval in healthcare. Over the past 25 years, her research interests have been in a variety of areas relating to artificial intelligence including computer vision, image and video databases, medical image analysis, bioinformatics, signal processing, document analysis, and distributed computing frameworks. She has over 100 refereed publications and over 40 issued patents. Dr. Syeda-Mahmood was the program co-chair of CVPR 2008 recently. She is a senior member of IEEE.


Patrick Terry CEO of Technic Solutions, Co-Founder of Genomic Health, Founder of Personalized Medicine Coalition

Patrick F. Terry is a social entrepreneur who has founded a series of philanthropic, research, and commercial organizations based on the life sciences, applied technology, and social-network theory. He is the co-founded of Genomic Health [NASDAQ: GHDX], and former Director at the pioneering personalized medicine company based in California. His perspective is forged from personal and family experiences with genetic disease, cancer, and extensive work in the patient advocacy community. He has published dozens of peer-reviewed scientific papers, articles, and book chapters in the fields of genetics, rare disease, and personalized medicine. Some of his recent activities included leadership positions on numerous trade associations, professional societies, corporate boards, and federal advisory bodies. He has experience doing hands-on bench science, coordinating genetics research, conducting research on rare diseases, and managing a life sciences patent portfolio. He has received many honors and awards in the business and scientific communities in the U.S. and internationally. He has dedicated his career to helping people and advancing a patient-centered perspective in research, product development, and delivery of care. He is currently a Director at Sirius Genomics, TcLand Expression, BioLogos Foundation, and GRAND Therapeutics. Patrick has also founded the following organizations: Personalized Medicine Coalition, 21st Century Medicine Coalition, PXE International, Genetic Alliance BioBank, International Genetic Alliance, European Personalized Medicine Diagnostic Association, and GRAND Therapeutics.
  Stephen Thau Partner Morrison Foerster    

Mr. Thau is co-chair of Morrison & Foerster’s 140-lawyer Life Sciences Group. His practice focuses on the representation of life science, medical device, and other technology companies at all stages of their life cycles, from company formation, equity and debt financing, merger and acquisition transactions, strategic alliances and public offerings. He also represents venture capital and investment banking firms in public and private financing transactions. He has represented companies and investors in over a hundred venture capital and debt financing transactions, as well as in numerous public offerings and public and private M&A transactions. Mr. Thau’s clients include AcelRx Pharmaceuticals, Allux Medical, Altair Therapeutics, Baxano, Catalyst Biosciences, DURECT Corporation, Horizon Therapeutics, Osteologix, SurModics and Visiogen. Mr. Thau also represents venture capital firms including CHL Medical Partners, CMEA Ventures, Prospect Venture Partners, Three Arch Partners and Thomas, McNerney & Partners and has represented underwriters including AG Edwards & Sons, Inc. and CS First Boston.


  Mickey S. Urdea Co-Founder, Chairman and Chief Executive Officer Tethys Bioscience, Inc.    

In the early 1980’s Dr. Urdea was one of the first employees at Chiron where he directed the nucleic acids chemistry group and began the molecular diagnostics efforts. He led the development of quantitative RNA and DNA assays, including the introduction of the first HIV and HCV viral load tests. He became head of the Nucleic Acid Diagnostics business unit at Chiron. In 1998, he joined Bayer Diagnostics as Senior Vice President of Nucleic Acid Diagnostics and acting-Chief Scientific Officer of Bayer Diagnostics. He left Bayer in 2000 and co-founded Tethys Bioscience in 2002. Dr. Urdea received a Ph.D. in biochemistry at Washington State University and held an NIH postdoctoral fellowship at UCSF with William J. Rutter. He has published more than 185 articles and book chapters, and is an inventor on more than 100 issued and pending patents.

  Paul J. Utz, M.D. Associate Professor of Medicine Immunology & Rheumatology Stanford University    

P.J. has expertise in the study of human and murine autoantibodies and autoantigens, apoptosis signaling pathways, animal models of autoimmunity, proteomics and microfluidics. Members of his laboratory are developing several cutting-edge proteomics technologies for immunological applications, including multiplex planar-based autoantigen microarrays and microfluidic CE assays. P.J. is actively involved with many educational programs within the University. He is director of the CCIS Summer High School Research Program, and he provides formal lectures to undergraduate, graduate, and medical students in the School of Medicine and the School of Engineering. He also teaches medical students, residents and fellows in the clinics and on the in-patient wards. Professor Utz is a member of the Scientific Advisory Boards of several Bay Area biotechnology companies. He is also actively involved in consulting with biotechnology companies.

  Vance Vanier, M.D. Chief Medical Officer Navigenics  

Dr. Vance Vanier is the Chief Medical Officer of Navigenics and a clinical faculty member of Stanford University Medical Center. As a former partner at venture capital firm, Mohr Davidow Ventures, he has spent years in the molecular diagnostics industry bringing new genomic technologies into clinical practice. Dr. Vanier received his medical degree from the Johns Hopkins School of Medicine and did his residency training at the University of California, San Francisco, and Highland Hospital in Oakland, Calif. He serves as a member of the Personalized Medicine Coalition's Clinical Science Committee, Stanford Hospital's Pharmacy and Therapeutics Committee, and the American College of Preventive Medicine. During his medical career, he has had a strong commitment to international medicine -- including traveling to Kosovo after the war to work with the World Health Organization in creating the nation's first ambulance system. He received an MBA from Stanford University, as well as dual bachelor's degrees with honors.

  Yael Weiss, MD, Ph.D. Licensing & External Research Merck & Co., Inc.    

Dr. Weiss completed her MSc and PhD in molecular genetics at the Weizmann Institute of Science, Rehovot, Israel and obtained her medical degree at Hadassah Medical Center, affiliated with The Hebrew University of Jerusalem, Israel. After practicing medicine for a few years, Dr. Weiss joined an Israeli venture capital firm as a vice president responsible for analyzing and maintaining deal flow, and then moved on to become a medical and business development director at Genzyme Israel. Dr. Weiss joined Merck's Israeli subsidiary as medical director in the beginning of 2004 and this summer joined Merck's Licensing group in San Francisco as a scientific scout responsible for identification of licensing opportunities emanating from the West Coast.


Alan H.B. Wu, Ph.D. Professor of Laboratory Medicine UCSF Pathology & Laboratory Medicine

Dr. Wu is Chief of Clinical Chemistry and Toxicology at San Francisco General Hospital and Professor of Laboratory Medicine, University of California, San Francisco. He received B.S. degrees in chemistry and biology at Purdue University, West Lafayette, Indiana, and a Ph.D. degree in analytical chemistry at the University of Illinois, Champaign-Urbana, Illinois. He completed a postdoctoral fellowship in clinical chemistry at Hartford Hospital. He is certified by the American Board of Clinical Chemistry in Clinical Chemistry and Toxicological Chemistry. Dr. Wu’s research interest has been in three areas within the field of clinical chemistry laboratory. He has been involved at the national and international levels with development and use of biochemical markers for cardiovascular disease including CK-MB, myoglobin, troponin, B-type natriuretic peptide, and markers of myocardial ischemia, and stroke. As also has a long history of analytical, clinical, and forensic toxicology. In both of these areas, Dr. Wu has co-authored the National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. More recently, Dr. Wu has developed research and clinical programs in pharmacogenomics in support of the UCSF clinical pharmacogenomics laboratory. Among the areas of interest include pharmacogenomics for anticoagulants, especially warfarin, chemotherapeutics (tamoxefin, irinotecan), and drugs that can induce hypersensitivity reactions (abacavir, anticonvulsants).